East Syracuse, NYNCT07099898Now EnrollingIRB Ready

Neoplasms, Lung Clinical Trial in East Syracuse, NY

Access cutting-edge neoplasms, lung treatment through this phase 3 clinical trial at a research site in East Syracuse. Study-provided care at no cost to qualified participants.

Sponsored by GlaxoSmithKline

Quick Self-Assessment

See if you qualify for this East Syracuse location

Preparing your pre-screening questions…

Expert Care in East Syracuse

Access neoplasms, lung specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasms, lung treatment provided free

Apply for This East Syracuse Location

Check if you qualify for this neoplasms, lung clinical trial in East Syracuse, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to East Syracuse

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit East Syracuse site if eligible
  4. 4Begin participation

About This Neoplasms, Lung Study in East Syracuse

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:
Adults \>18 or the minimum legal adult age at the time the informed consent form is signed
Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of \>30 days, with documented progression. Participants with prior tarlatamab treatment in either the first- or second-line ES-SCLC setting are eligible.
Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
Has adequate organ function and an ECOG performance status of 0 or 1

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:
Pathological diagnosis of complex SCLC or transformed SCLC.
Limited stage small cell lung cancer at diagnosis
Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3.
Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
Has severe, uncontrolled or active cardiovascular disorders.
Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).
Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases.
Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids.
Has significant pulmonary disease or respiratory impairment (e.g., uncontrolled asthma/COPD, restrictive lung disease),
Has active Hepatitis B or Hepatitis C

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in East Syracuse?

Yes, this clinical trial (NCT07099898) has an active research site in East Syracuse, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasms, Lung Treatment Options in East Syracuse, NY

If you're searching for neoplasms, lung treatment options in East Syracuse, NY, this clinical trial (NCT07099898) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our East Syracuse research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced neoplasms, lung specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasms, lung clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in East Syracuse, NY

See all multiple sclerosis clinical trials recruiting in East Syracuse — not just this study.

Browse Multiple Sclerosis Trials in East Syracuse →

Browse More Trials by Condition

Multiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in East Syracuse?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · East Syracuse, NY